cibinetide   Click here for help

GtoPdb Ligand ID: 9677

Synonyms: ARA 290 | ARA-290 | PH-BSP | PHBSP
Immunopharmacology Ligand
Comment: Cibinetide (ARA 290) is an engineered peptide that mimics the 3 dimensional structure of the helix B surface domain of erythropoietin (EPO). It is designed to bind selectively to the non-hematopoietic EPO receptor (sometimes referred to as the innate repair receptor or IRR), that is believed to be a heterodimer of EPOR and the cytokine family beta common receptor (βCR, CD131) [1-2]. Non-hematopoietic EPO ligands have potential tissue protective and anti-inflammatory actions [4-6,8-10]. The IRR is suggested to be a point of integration between the immune system and pain signalling (via nociception) [11].
Cibinetide is SEQ ID NO. 282 (and peptide ID) as claimed in patent WO2009094172 [3].
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCC(C(=O)NC(C(=O)O)CO)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C1CCC(=O)N1)CCC(=O)O)CCC(=O)N)CC(C)C)CCC(=O)O)CCCN=C(N)N)C)CC(C)C)CC(=O)N
Isomeric SMILES OC[C@@H](C(=O)N[C@H](C(=O)O)CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)CCC(=O)O)CCC(=O)N)CC(C)C)CCC(=O)O)CCCN=C(N)N)C)CC(C)C)CC(=O)N
InChI InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
InChI Key WZTIQQBMSJTRBR-WYKNNRPVSA-N
No information available.
Summary of Clinical Use Click here for help
Cibinetide (under research code ARA 290) is a phase 2 clinical candidate or neuropathic and retinal diseases. Orphan drug designation has been granted by the US FDA (treatment of neuropathic pain in patients with sarcoidosis, treatment of sarcoidosis) and the EMA (prevention of graft loss in pancreatic islet transplantation, treatment of sarcoidosis).